Wysdom Radio™

Wysdom

5.0 (2)
Medicine

We deliver short, focused episodes on the main concepts and procedures you actually need to know. It’s the perfect clinical companion for your drive to work or your daily workout. Come learn IR on the go! Check us out at https://www.medicalwysdom.ai/

5d ago

Beyond the Drug: What Makes TACE Work?

This episode breaks down PRECISION V, the 2010 randomized trial that helped make drug-eluting beads a standard option for hepatocellular carcinoma (HCC), and tests its conclusions against later bland-bead and anatomy data. Following, there is an expert commentary by Dr. Premal Trivedi, Chief of Interventional Radiology at the University of Colorado. The Premise: Conventional TACE uses an unstable lipiodol emulsion that leaks doxorubicin into the systemic circulation. Drug-eluting beads promised to hold the drug in the tumor and block flow permanently.Efficacy: In about 200 BCLC A/B patients, six-month objective response was 51.6% with DC Bead versus 43.5% with conventional TACE (p = 0.11), so the trial missed its primary endpoint. A post hoc advanced-disease subgroup favored the beads (52.4% versus 34.7%).Toxicity: Bead patients received more doxorubicin but had far less alopecia (1.1% versus 20.4%), lower peak ALT and preserved LVEF. Post-embolization syndrome was nearly identical.The Catch: The MSKCC Brown trial compared doxorubicin-loaded beads with bland beads and found essentially the same response and survival, which suggests ischemia, not the drug, is doing the work.Caveats: The trial was an industry-sponsored phase II study with six months of follow-up and no survival endpoints. It was underpowered once the control arm outperformed expectations.Expert Take: Dr. Trivedi notes that systemic doxorubicin alone yields only about a 10% response in HCC, and that most of TACE's benefit comes from the depth and completeness of ischemia.Tune in to learn why the embolization, not the chemotherapy, may be doing the heavy lifting in TACE. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52.
Sep 30

Infra-popliteal Bioresorbable Stents: The NEJM LIFE-BTK Trial

This episode breaks down LIFE-BTK, the 2024 New England Journal of Medicine randomized trial testing whether a drug-eluting resorbable scaffold beats plain balloon angioplasty for infrapopliteal artery disease in chronic limb-threatening ischemia. The Premise: Below the knee has been a graveyard of failed devices. A scaffold that resists recoil, elutes an antiproliferative drug, then dissolves promises structural support without a permanent metal cage.Efficacy: In 261 CLTI patients randomized 2:1, one-year freedom from the primary composite was 74% with the scaffold versus 44% with angioplasty, though the separation was driven largely by binary restenosis (76% versus 50%).Acute Mechanics: Core-lab technical success was 91% versus 70%, with bailout stenting needed in 6% of angioplasty cases and none in the scaffold arm.The Catch: Every major safety event was in the scaffold arm, including two perioperative deaths and four above-ankle amputations, three in limbs with patent scaffolds. Wound healing was numerically lower (45% versus 56%).Durability: As the scaffold resorbs, the benefit holds. At three years the composite endpoint remained higher for the scaffold, 59.5% versus 44.8%.Caveats: Only about 3% of screened patients enrolled, lesions were short and lightly calcified, vessel prep was mandatory only in the scaffold arm, and DAPT ran 12 months versus 1, all favoring the scaffold.Tune in to learn how the first fully resorbable below-the-knee scaffold stacked up against angioplasty, and where the trial's design should temper how you apply it. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Varcoe RL, DeRubertis BG, Kolluri R, et al. Drug-eluting resorbable scaffold versus angioplasty for infrapopliteal artery disease. N Engl J Med. 2024;390:9-19. https://doi.org/10.1056/NEJMoa2305637
Sep 23

Fractured IVC Filter Fragments: The Penn Perspective

This episode features expert commentary from Dr. Scott Trerotola of Penn Medicine, responding to our recent episode on Stanford's fractured IVC filter registry titled, Fractured IVC Filter Fragments: When to Chase the Metal. Shared Ceiling: Both the Penn and Stanford series found that, at best, about half of patients leave with every fragment removed. Some extravascular fragments can still be reached by direct CT- or fluoro-guided puncture.Pulmonary Is Not a Parking Spot: Dr. Trerotola argues that a fragment moving from the heart into the lungs is not a success. Fragments can be coughed up or reach the systemic circulation, and removal is low risk in experienced hands.Radiation in Perspective: Penn's median fluoroscopy time was 27 minutes, so dose should not drive the decision.Tune in to hear why a fragment in the lung is still worth chasing.
Sep 16

The Golden Era of PE Trials: PRAGUE-26

This episode breaks down PRAGUE-26, a 558-patient NEJM randomized trial from 11 Czech centers testing whether low-dose thrombolysis through cheap generic infusion catheters beats anticoagulation alone, with expert commentary throughout from Dr. Jay Giri of Penn Medicine. The Protocol: Standard 4 French infusion catheters, no ultrasound facilitation, alteplase capped at 20 mg over a mean infusion of 9.3 hours. Median time from randomization to lysis was 76 minutes.The Result: The 7-day composite of death, recurrent PE, or cardiorespiratory decompensation fell from 6.8% to 0.7%, with faster RV recovery and shorter ICU stays.What Drove It: Decompensation, not mortality. The endpoint included a NEWS score of 9 or higher, more sensitive than the vasopressor or arrest criteria used in PEITHO.The Bleeding Tradeoff: Major bleeding was neutral, but two intracranial hemorrhages occurred in the thrombolysis arm versus zero with anticoagulation.The Cost Argument, Examined: Generic catheters are cheaper to buy, but Dr. Giri notes that US reimbursement places EKOS cases in a different DRG that covers the catheter. This was also not a head-to-head test of ultrasound facilitation.Caveats: Open-label with an unblinded events committee, no screening logs, a single homogeneous population, and no one over 80.Tune in to learn where this trial actually moves the needle, and where the enthusiasm outruns the data. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Kroupa J, Radvan M, Mrozek J, et al. Catheter-directed thrombolysis in intermediate-high-risk pulmonary embolism. N Engl J Med. Published online August 31, 2026. doi:10.1056/NEJMoa2608012
Sep 9

The Heparin Paradox: When More is Less

This episode breaks down a 2026 JVIR letter to the editor describing intraprocedural heparin resistance during iliocaval thrombectomy in a 67-year-old man with stage IV diffuse large B-cell lymphoma and recurrent DVT. The Setup: A chest wall hematoma on therapeutic heparin forced cessation of anticoagulation and IVC filter placement. Two weeks later, thrombus extended from below the filter into the bilateral iliocaval and femoral segments (Villalta 15 to 18, VCSS 12).The Pharmacologic Wall: Despite 13,000 units of heparin (roughly 136 U/kg) targeting an ACT above 250 seconds, values sat at 133 to 138 with thrombus reaccumulating during active aspiration. Day two brought 21,000 units and a unit of FFP, moving the ACT only from 173 to 198.Why It Failed: The 4Ts score was 2, arguing against HIT. Antithrombin III fell from 89% at baseline to 52% post-procedure, pointing to acquired consumption rather than hereditary deficiency.The Algorithm: Confirm dosing, exclude sampling error, then escalate beyond repeat heparin. Options include anti-factor Xa-guided dosing, ATIII concentrate rather than FFP in a volume-overloaded patient, or a direct thrombin inhibitor that does not require ATIII.The Mechanical Half: Filter retrieval and femorotibial venoplasty addressed the thrombogenic nidus and the restricted inflow, since central clearance does not hold without runoff.Caveats: A single case with three problems corrected at once. Neither a direct thrombin inhibitor nor ATIII concentrate was actually given, leaving the recommended pathway untested.Tune in to learn why escalating heparin against a flat ACT wastes table time, and what to reach for instead. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Seo Y, Ahuja T, Chen M, Ranade M. Heparin resistance during iliocaval thrombectomy in a hypercoagulable patient. J Vasc Interv Radiol. 2026. https://doi.org/10.1016/j.jvir.2026.109018
Sep 2

Fractured IVC Filter Fragments: When to Chase the Metal

This episode breaks down a 5-year Stanford registry of 82 patients presenting with fractured IVC filters and 185 embolized fragments, with commentary from both Dr. Andrew Kesselman, from Stanford Medicine, and Dr. Scott Trerotola, from Penn Medicine. The question is which fragments to chase and which to leave alone. Triage Comes First: Only 87 of 185 fragments (47%) were deemed intravascular and amenable to removal. Retroperitoneal fragments and peripheral pulmonary artery fragments were left alone by protocol, since traction on an extravascular strut risks caval avulsion.Geographic Gradient: Technical success was 100% for caval fragments (65 of 65), 64% in the proximal pulmonary arteries, and 50% for both cardiac and hepatic vein fragments, with an overall rate of 89.7%.The Cardiac Penalty: The one major complication in the series was a cardiac tamponade during right ventricular fragment removal, giving a 12.5% major complication rate for cardiac attempts. With only 8 attempts, the confidence interval runs from 0.3% to 52.7%, so the signal is directional rather than a number to quote in consent.Natural History: Among 19 patients with retained cardiopulmonary fragments, 81% remained asymptomatic at a mean follow-up of 845 days, which supports surveillance for embedded, inaccessible metal.Tools by Zone: Rigid endobronchial forceps dissect through neointimal hyperplasia in the cava, where a snare slips off endothelialized metal. Cardiopulmonary work shifts to snares with a steerable sheath to avoid the subvalvular apparatus.Caveats: Single center with more than 90% outside referrals and over half having failed prior attempts. The headline success rate applies only to the 47% of fragments selected for an attempt, and radiation burden was never quantified.Tune in to learn why the hardest part of fragment retrieval is deciding which pieces to walk away from. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.Kesselman AJ, Hoang NS, Sheu AY, Kuo WT. Endovascular removal of fractured inferior vena cava filter fragments: 5-year registry data with prospective outcomes on retained fragments. J Vasc Interv Radiol. 2018;29(6):758-764.
Aug 26

Procedural Path to 91% Complete Pathologic Necrosis

This episode breaks down COBRAS, a 2026 Radiology multicenter study of 303 patients and 364 treatment-naive HCC tumors bridged to liver transplant with glass microsphere radiation segmentectomy. Listen to the end to hear an expert commentary by Dr. Sid Padia from UCLA Interventional Radiology. Four Parameters: Microsphere activity of at least 1,087 Bq, at least 8,000 microspheres per mL, a single-compartment dose of at least 400 Gy, and an angiosome-to-tumor ratio of 16 or greater.Stacked Result: Positive predictive value for complete pathologic necrosis rose from 74% with activity alone to 91% with all four thresholds met. Meeting none carried a 78% failure rate.Biggest Lever: ATR had the highest odds ratio in the model at 3.4, which argues for pulling the catheter proximal to cover occult parasitic feeders rather than superselecting to the tumor border.Caveats: Retrospective, glass microspheres only, limited to patients who reached transplant, and CPN remains a surrogate endpoint not yet tied to long-term survival.Tune in to learn why the physics inside the vial and the position of your catheter may matter as much as the dose number on the screen. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.Berman ZT, De la Garza-Ramos C, Montazeri SA, et al. Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma. Radiology. 2026;319(2):e251923.
Aug 20

Treat the Patient, Not the Picture: Rethinking Pelvic Venous Disease

This episode breaks down the latest Society of Interventional Radiology guidance on chronic pelvic pain of venous origin, focusing on patient selection and why technically successful procedures may not relieve pain. It concludes with expert commentary from Dr. Gloria Salazar of the UNC School of Medicine. Beyond the Old Labels: The Symptoms-Varices-Pathophysiology classification replaces older labels and distinguishes reflux from obstruction.Pain Is More Than Plumbing: Pelvic floor tension and nervous system sensitization may persist after the venous abnormality is treated.The Supine Imaging Trap: Left renal vein compression changes dramatically with position, making static imaging alone unreliable.Protect the Renal “Pop-Off Valve”: A pressure gradient above 3 mm Hg during ovarian vein occlusion may indicate essential collateral drainage.Technical Pearls: Proper sclerosis, embolic sizing, anchoring, and stent landing zones help prevent treatment failure.Stent or Embolize: Conflicting outcomes show why treatment must target the patient’s dominant pain mechanism.Tune in to learn why pelvic venous interventions should be guided by symptoms and dynamic hemodynamics, not abnormal anatomy alone. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.Kaufman CS, Winokur RS, Khilnani NM, et al. The Society of Interventional Radiology Practice Guidance Document on Venous-Origin Chronic Pelvic Pain in Women. J Vasc Interv Radiol. 2026;37:107954.

5

out of 5

2 Ratings

We deliver short, focused episodes on the main concepts and procedures you actually need to know. It’s the perfect clinical companion for your drive to work or your daily workout. Come learn IR on the go! Check us out at https://www.medicalwysdom.ai/

Creator

Wysdom
Years Active

2025 - 2026
Episodes

52
Rating

Clean
Copyright

© 2026 Wysdom
Show Website

Wysdom Radio™

Investing

Investing

Updated Semiweekly
Medicine

Medicine

Updated Bimonthly
Technology

Technology

Updated Weekly
Medicine

Medicine

Updated Weekly
Politics

Politics

Updated Weekly
Business

Business

Updated Semiweekly